Compound ID | 163
Class: Oxazolidinone
| Spectrum of activity: | Gram-positive |
| Details of activity: | Gram-positive infections including MRSA. |
| Institute where first reported: | MicuRx Pharmaceuticals, USA |
| Year first mentioned: | 2015 |
| Highest developmental phase: | Preclinical |
| Development status: | Active |
| External links: | |
| Citation: |